Safety Reading Notes

Read safety context beside the research guide.

The Cannabinoids and pregnancy/pediatrics safety review source set includes safety-context rows around pregnancy, lactation, pediatric, adolescent, or developmental contexts: insufficient. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 37648266

Evidence class: insufficient

PubMed For Dummies Article

Cannabinoids and pregnancy/pediatrics safety review Evidence Review: the long-form source walk-through

Quick read
  • Cannabinoids and pregnancy/pediatrics safety review currently has 30 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 37648266
  • The evidence classes most visible in the row language are insufficient (24), preliminary human (4), mechanistic or pharmacological (1), and preclinical (1). PMID 40164212
  • The study-design language most visible in the row language is Narrative or expert review (13), Systematic review (3), Human clinical study (3), and other mapped categories (3). PMID 35903331
  • The repeated topics are pregnancy, lactation, pediatric, adolescent, or developmental contexts (30), which tells the reader where to start opening PubMed and DOI links. PMID 40589083

Start with the research question

Cannabinoids and pregnancy/pediatrics safety review is built from 30 source-backed evidence row(s) and 30 research source(s). The current evidence classes read as insufficient (24), preliminary human (4), mechanistic or pharmacological (1), and preclinical (1), and the study-design language most often reads as Narrative or expert review (13), Systematic review (3), Human clinical study (3), and other mapped categories (3). PMID 37648266

The row-level question is not simply whether Cannabinoids and pregnancy/pediatrics safety review is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are pregnancy, lactation, pediatric, adolescent, or developmental contexts (30). PMID 37729034

Human evidence 4 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 34035677

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39903192

Mechanistic evidence 1 row

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 36730710

Limits and uncertainty 24 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37729034

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 38469628

Where this page has the most source density

The largest bucket surfaced for this page is pregnancy, lactation, pediatric, adolescent, or developmental contexts: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is pregnancy, lactation, pediatric, adolescent, or developmental contexts: preliminary human, which gives readers another way to see what the literature repeatedly circles. PMID 37648266

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 37729034

Bucket chapters: what the literature is circling

pregnancy, lactation, pediatric, adolescent, or developmental contexts: insufficient

24 research sources 24 rows (98-195) Evidence class: insufficient

This bucket summarizes source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts: insufficient. It currently draws from 24 research source(s), so the exact study type matters. PMID 37648266

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37648266

  • Evidence row 98

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review... PMID 37648266

  • Evidence row 195

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrativ... PMID 37330589

pregnancy, lactation, pediatric, adolescent, or developmental contexts: preliminary human

4 research sources 4 rows (105, 183, 186, 187) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts: preliminary human. It currently draws from 4 research source(s), so the exact study type matters. PMID 37729034

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37729034

  • Evidence row 105

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure:... PMID 37729034

  • Evidence row 183

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy... PMID 38627667

pregnancy, lactation, pediatric, adolescent, or developmental contexts: mechanistic or pharmacological

1 research source 103 Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts: mechanistic or pharmacological. It currently draws from 1 research source(s), so the exact study type matters. PMID 39903192

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 39903192

  • Evidence row 103

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design:... PMID 39903192

pregnancy, lactation, pediatric, adolescent, or developmental contexts: preclinical

1 research source 191 Evidence class: preclinical

This bucket summarizes source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts: preclinical. It currently draws from 1 research source(s), so the exact study type matters. PMID 41840986

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 41840986

  • Evidence row 191

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preclinical (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Animal study; outc... PMID 41840986

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (4 row(s)), mechanistic evidence (1 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 37648266

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 37729034

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 36206805
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 41296368
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 28847562

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 37648266

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 37729034

Source-reading checklist for Cannabinoids and pregnancy/pediatrics safety review

  1. Open the linked PubMed or DOI record. PMID 35662548
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 34021274
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 32943535
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 25439854
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 37651516

Source Notes

Cannabinoids and pregnancy/pediatrics safety review source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 98

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37648266

    Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
  2. Evidence row 99

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40164212

    Evidence class: insufficient; Study design: Narrative or expert review. Source: High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation.
  3. Evidence row 100

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 35903331

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.
  4. Evidence row 101

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40589083

    Evidence class: insufficient; Study design: Systematic review. Source: Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.
  5. Evidence row 102

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 34035677

    Evidence class: insufficient. Source: Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.
  6. Evidence row 103

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 39903192

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model.
  7. Evidence row 104

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 36730710

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis.
  8. Evidence row 105

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37729034

    Evidence class: preliminary human. Source: Variation in Hospital Practices Regarding Marijuana Use in Pregnancy and Lactation.
  9. Evidence row 106

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 38469628

    Evidence class: insufficient. Source: Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study.
  10. Evidence row 175

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 36206805

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
  11. Evidence row 176

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  12. Evidence row 177

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 28847562

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis use during pregnancy: Pharmacokinetics and effects on child development.
  13. Evidence row 178

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 35662548

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.
  14. Evidence row 179

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 34021274

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and synaptic reprogramming of the developing brain.
  15. Evidence row 180

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 32943535

    Evidence class: insufficient. Source: Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect.
  16. Evidence row 181

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 25439854

    Evidence class: insufficient; Study design: Narrative or expert review. Source: [Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review].
  17. Evidence row 182

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37651516

    Evidence class: insufficient. Source: Smoke Alarm.
  18. Evidence row 183

    THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 38627667

    Evidence class: preliminary human. Source: Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.
  19. Evidence row 184

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40353977

    Evidence class: insufficient. Source: Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure.
  20. Evidence row 185

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40121379

    Evidence class: insufficient. Source: Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old.
  21. Evidence row 186

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 26724101

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
  22. Evidence row 187

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 25479151

    Evidence class: preliminary human; Study design: Human clinical study. Source: Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.
  23. Evidence row 188

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 33754312

    Evidence class: insufficient; Study design: Systematic review. Source: Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
  24. Evidence row 189

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 42057496

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.
  25. Evidence row 190

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 32661188

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Marijuana and the Pediatric Population.
  26. Evidence row 191

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preclinical (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Animal study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41840986

    Evidence class: preclinical; Study design: Animal study. Source: Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.
  27. Evidence row 192

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 27139708

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.
  28. Evidence row 193

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41683846

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System.
  29. Evidence row 194

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 33800053

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy.
  30. Evidence row 195

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37330589

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy.